investor.anninc.com
ANN INC. - Investors - Overview
160; 0.08. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. ANN INC. and Vital Voices Global Partnership Empower 50 ANNpower Fellows at Fourth Annual Leadership Forum. ANN INC. Reports First Quarter 2015 Results. Ascena Retail Group, Inc. To Acquire ANN INC. For $47 Per Share In Accretive Transaction. There are currently no events scheduled. Sign up to receive e-mail alerts whenever ANN INC. posts new information to the site. Just enter your e-mail address and click Submit. Contact the Board of.
investor.anntaylor.com
ANN INC. - Investors - Overview
160; 0.08. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. ANN INC. and Vital Voices Global Partnership Empower 50 ANNpower Fellows at Fourth Annual Leadership Forum. ANN INC. Reports First Quarter 2015 Results. Ascena Retail Group, Inc. To Acquire ANN INC. For $47 Per Share In Accretive Transaction. There are currently no events scheduled. Sign up to receive e-mail alerts whenever ANN INC. posts new information to the site. Just enter your e-mail address and click Submit. Contact the Board of.
investor.anthera.com
Investor Relations | Anthera Pharmaceuticals, Inc.
Skip to main navigation. Phone: 1.510.856.5600. We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Delayed at least 20 minutes. March 12, 2018. Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura. March 7, 2018. Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference. View all press releases. March 12, 2018. March 12, 2018. View all events and presentations.
investor.aosmd.com
Investor Overview | Alpha and Omega Semiconductor
Skip to main navigation. 31616;体中文. Powering a Greener Future ™. Investor Information and Tools. Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer and global supplier of a broad range of power semiconductor products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables us to introduce innovative products to address the increasingly complex power requirements of adva...
investor.aosmith.com
Investor Relations - A.O. Smith Corporation
Looking for a water heater? July 23, 2015. A O Smith reports record earnings on strong global sales growth; raises full year EPS guidance over 10 percent. July 1, 2015. A O Smith to hold second quarter conference call on July 23. View all financial releases ». August 13, 2015. 2015 Summer Investor Presentation. July 23, 2015 at 10:00 AM ET. Second Quarter 2015 Earnings Call. May 27, 2015. Spring 2015 Investor Presentation. View all events and presentations ». A O Smith Water Heaters: See How They're Made.
investor.appliedmicro.com
AppliedMicro - Powering Your Cloud Network - Investor Relations - Investor Relations
Applied Micro Circuits Corporation at Oppenheimer Technology, Internet and Communications Conference. 160;at 10:25 am ET. Applied Micro Circuits Corporation at Oppenheimer Technology, Internet and Communications Conference. Wednesday, August 12, 2015 . 10:25 am ET . Click here for webcast. Click here to add this event to your calendar. Applied Micro Circuits Corporation at Canaccord Genuity Growth Conference. 160;at 11:00 am ET. Applied Micro Circuits Corporation at Canaccord Genuity Growth Conference.
investor.aqxpharma.com
Investor Relations - Aquinox Pharmaceuticals, Inc
Activate excellence. Activate innovation. Activate success. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Aquinox Pharmaceutical Inc's financial performance into perspective. Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC and Reports Second Quarter 2015 Financial Results. View all press releases ». 8/13/15 at 3:00 PM ET.
investor.aradigm.com
Investor Relations | Aradigm Corporation
Skip to main navigation. Mar 29, 2018. Transfer Agent and Registrar. Communications concerning stock transfer requirements, lost certificates and change of address should be directed to:. Shareholder correspondence should be mailed to:. College Station, TX 77842-3170. Overnight correspondence should be sent to:. 211 Quality Circle, Suite 210. College Station, TX 77845. Https:/ www-us.computershare.com/investor/Contact. Mar 23, 2018. Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results.
investor.arbutusbio.com
Arbutus Biopharma - Investor Relations
The Baruch S. Blumberg Institute. Surface Antigen Secretion Inhibitors. Oncology, Anti-virals and Metabolic Programs. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:TKMR. In addition to our HBV Assets. We are developing a pipeline of Oncology, Anti-viral and Metabolic Programs. That leverage our expertise in RNA interference (RNAi). Therapeutics and our Lipid Nanoparticle (LNP). View all ». Aug 7, 2015. Aug 5, 2015. View all ».
investor.archcoal.com
Arch Coal, Inc. | Investors: Investor Relations Home
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Arch Coal's performance into perspective. Arch Coal is listed on the New York Stock Exchange (NYSE: ACI) and maintains its corporate headquarters in St. Louis, Mo. Arch Coal, Inc. Reports Second Quarter 2015 Results. Supplemental Historical Information Regional Realization and Cost Analysis. 2014 Annual Report Narrative. Or www.amstock.com.
investor.ariad.com
ARIAD Pharmaceuticals, Inc: Investor home
Our Name and Logo. Our Vision, Mission and Values. Our Vision, Mission and Values. Key to long-term value: discipline, execution and consistent communication. ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer an...
